This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Ion interaction chromatography (ion-pair chromatography) is a laboratory technique for separating ions with chromatography. In this technique ions are mixed with ion pairing reagents (IPR). The analyte combines with its reciprocal ion in the IPR, this corresponds to retention time. Often organic salts are selected to pair with solute(s). The formation of this pair affects the interaction of the pair with the mobile phase and the stationary phase.
Moroccans (mainly from the Rif region) have migrated in large waves to the Benelux, who were invited to these countries as guest workers. This dense and rather late emigration in the 1960s and 1970s eventually never stopped, and many of the invited guest workers decided to build a new life in the Benelux instead. Most of these Moroccan immigrants came from the Rif region, which is one of the poorest regions in all of Morocco. The Rif region was, and still is a very rural and little urbanised area, which had very few schools for an excessive time, whether in Arabic or French. This Mediterranean peasant and mountain society is quite comparable to other Mediterranean regions like Corsica, Sicily, Sardinia, Calabria and the Aurès. It is characterised by very strong community relationships, a spirit of silence (omertà) and self-governance. This mountainous region has always stayed somewhat uncontrollable. After decolonisation, more than tens of thousands of Riffians lost their jobs in the vineyards and farms of Morocco and Algeria. Afterward, this process continued, as if from the 1970s and onwards, many of these migrated Riffians have lost their jobs in the European mines and steel industry as well. Since then this workforce has converted on a massive scale into different ways of commerce and businesses, both legal and illegal, with the illegal side, in particular, being the smuggling of cannabis. The earned money was reinvested in cafes, small businesses and real estate in Morocco.
==== Oxygen ==== Oxygen isotopic ratios are commonly compared to both the VSMOW and the VPDB references. Traditionally oxygen in water is reported relative to VSMOW while oxygen liberated from carbonate rocks or other geologic archives is reported relative to VPDB. As in the case of hydrogen, the oxygen isotopic scale is defined by two materials, VSMOW2 and SLAP2. Measurements of sample δ18O vs. VSMOW can be converted to the VPDB reference frame through the following equation: δ18OVPDB = 0.97001*δ18OVSMOW - 29.99‰ (Brand et al., 2014).
Sources: en.wikipedia.org
Instead, the company offered to provide the medication free through its patient access program for hardship cases, though this option was described as much more restrictive. Oncologists criticized the decision as unprecedented, with Dr. Carmen de Ramon Ortiz of Geneva University Hospital noting that about 20% of follicular lymphoma patients require intensive treatment and that Lunsumio represents "a very innovative immunotherapy that stimulates the immune system, leading to high remission rates." Industry experts characterized the withdrawal as a form of healthcare rationing and a "canary in the coal mine," noting that only half of EU-approved medications are available in Switzerland. Some experts suggested the withdrawal reflected broader pressures from potential U.S. pricing reforms and trade uncertainties that could affect Roche's largest market, including potential tariff increases on pharmaceutical exports from 10% to up to 31%. The case was viewed by analysts as a potential precedent-setting "regulatory showdown" that could influence pharmaceutical pricing negotiations across the industry, particularly for rare disease treatments affecting small patient populations.
== Applications == Matrix-assisted laser desorption ionization (MALDI) is a pulsed ionization technique that is readily compatible with TOF MS. Atom probe tomography also takes advantage of TOF mass spectrometry. Photoelectron photoion coincidence spectroscopy uses soft photoionization for ion internal energy selection and TOF mass spectrometry for mass analysis. Secondary ion mass spectrometry commonly utilizes TOF mass spectrometers to allow parallel detection of different ions with a high mass resolving power. Stefan Rutzinger proposed using TOF mass spectrometry with a cryogenic detector for the spectrometry of heavy biomolecules.
== History == Mobocertinib was studied in participants with previously treated metastatic non-small cell lung cancer with EGFR exon 20 insertions. The FDA granted the application for mobocertinib orphan drug designation.
== Treatment == Treating hypersomatotropism involves treating both the hypersomatotropism and the diabetes mellitus. Sometimes treatment is limited to the diabetes due to owners not wishing to treat the hypersomatotrism due to the associated costs. Monitoring of blood glucose levels is imperative as if improvement or resolution of insulin resistance is not identified hypoglycaemia can occur, leading to death. In dogs with progestogen induced hypersomatotropism the administration of progestogens should cease immediately. For cases derived from a mammary tumour it should be surgically removed.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.